Cargando…

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study

BACKGROUND: Clozapine, an antipsychotic with unique efficacy in treatment-resistant psychosis, is associated with increased susceptibility to infection, including pneumonia. AIMS: To investigate associations between clozapine treatment and increased risk of COVID-19 infection in patients with schizo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Govind, Risha, Fonseca de Freitas, Daniela, Pritchard, Megan, Hayes, Richard D., MacCabe, James H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417985/ https://www.ncbi.nlm.nih.gov/pubmed/32713374 http://dx.doi.org/10.1192/bjp.2020.151

Ejemplares similares

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment
por: Legge, Sophie E., et al.
Publicado: (2016)

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

The side effect profile of Clozapine in real world data of three large mental health hospitals
por: Iqbal, Ehtesham, et al.
Publicado: (2020)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
por: Shirazi, Ayala, et al.
Publicado: (2016)

Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
por: Barnes, Thomas R. E., et al.
Publicado: (2020)

Ethnic disparities in clozapine prescription for service-users with schizophrenia-spectrum disorders: a systematic review
por: Ventura, Anita Margarette Bayya, et al.
Publicado: (2022)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy – ERRATUM
por: Segev, Aviv, et al.
Publicado: (2021)

Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020)

Clinical correlates of early onset antipsychotic treatment resistance
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study
por: Johannsen, Claas-Frederik, et al.
Publicado: (2022)

A predictor model of treatment resistance in schizophrenia using data from electronic health records
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

It is time to start taking tobacco seriously as a risk factor for psychosis: self‐medication cannot explain the association
por: MacCabe, J. H.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4h9d30jo235do88buu335hgpns